Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 18/20 | 0.53 |
| ▸ | SMO | Q99835 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3013722 | 0.88 | NR3C1 (0.53) | NR3C1SMOCYP11B1CYP11B2 | |
| SCHEMBL2999648 | 0.87 | NR3C1 (0.54) | NR3C1SMOCYP11B1CYP11B2 | |
| SCHEMBL3006395 | 0.87 | NR3C1 (0.51) | NR3C1 | |
| SCHEMBL3000031 | 0.85 | NR3C1 (0.54) | NR3C1SMOPGR | |
| SCHEMBL3009515 | 0.84 | NR3C1 (0.57) | NR3C1CYP11B1CYP11B2PGR | |
| SCHEMBL4281198 | 0.80 | NR3C1 (0.65) | NR3C1SMOPGR | |
| SCHEMBL3000181 | 0.79 | NR3C1 (0.54) | NR3C1CYP11B1CYP11B2PGR | |
| SCHEMBL3011468 | 0.78 | NR3C1 (0.57) | NR3C1SMOARPGR | |
| SCHEMBL4287959 | 0.77 | NR3C1 (0.54) | NR3C1SMOPGR | |
| SCHEMBL3010734 | 0.77 | NR3C1 (0.57) | NR3C1CYP11B1CYP11B2ARPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658637-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-25 | — | — | US | claimed |
| US-20100197678-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | claimed |
| EP-2102170-A2 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2009-09-23 | — | — | EP | claimed |
| WO-2008070507-A2 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-06-12 | — | — | WO | claimed |
| US-8658637-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-25 | — | — | US | disclosed |
| US-8658637-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-25 | — | — | US | disclosed |
| US-8658637-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-25 | — | — | US | disclosed |
| US-20100204246-A1 | 5-AMINOPYRAZOL-3-YL-3H-IMIDAZO (4,5-B) PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2010-08-12 | — | — | US | disclosed |
| US-20100197678-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
| US-20100197678-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
| US-20100197678-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
| WO-2008070507-A2 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204246-A1 | 5-AMINOPYRAZOL-3-YL-3H-IMIDAZO (4,5-B) PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | ABL1, MCL1, ETV6 | NR3C1 2087/4885SMO 2903/4885CYP11B1 311/4885 |
| US-20100197678-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | NR3C1, NR3C2, MC2R | NR3C1 1/4885SMO 4451/4885CYP11B1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.